Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Jung E, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le X, Bast RC, Park S, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2011, 118: 2603-2614. PMID: 22370716, PMCID: PMC3864019, DOI: 10.1002/cncr.26565.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPositive breast cancerMiR-210 levelsBreast cancerMiR-210Cancer patientsMicroRNA expression levelsTumor presenceExpression levelsPlasma samplesBT474 cellsNeoadjuvant trastuzumab-based chemotherapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Trastuzumab-resistant breast cancer cellsMiR expression levelsTrastuzumab-based chemotherapyPathologic complete responseGrowth factor receptor 2Cancer cellsPostoperative plasma samplesPreoperative plasma samplesReverse transcriptase-polymerase chain reactionQuantitative reverse transcriptase-polymerase chain reactionMiR-210 expression